On September 2, 2020, the New England Journal of Medicine published encouraging clinical trial results showing that Amylyx Pharmaceuticals’ AMX0035 brought statistically significant benefit to people living with ALS.
The ALS Association and I AM ALS immediately called on the drug company and the FDA to make the treatment widely available as soon as possible. Data from the trial indicates the drug met its pre-specified, primary outcome and represents a significant development for the ALS community.
Proposal Central by Altum helps organizations like the ALS Association unlock the full potential of their research funding efforts and deliver outcomes that benefit humanity faster. With 20 years of historical data, Proposal Central also enables funding organizations to identify rising stars within the research community. Interestingly, Amylyx Pharmaceuticals was started by two undergraduates at Brown University in their dorm room in 2013.
You can read more about this recent breakthrough for ALS here.
